Toraskar has been keen on utilizing an accessible platform with digital biomarkers
Sonde Health of Boston and Mumbai-based Koye Pharmaceuticals have signed a multi-year agreement to develop a new vocal biomarker detection and monitoring capability for chronic obstructive pulmonary disease (COPD) in India.
The arrangement will allow Koye to develop solutions that help track and treat respiratory health in COPD patients using their voice, said PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) of Boston, the founder of Sonde.
Sonde Health and Koye Pharmaceuticals plan to develop more vocal biomarkers during their multi-year arrangement.
“This collaboration marks a major milestone in Sonde Health’s growth and evolution, and we’re excited to take this step with Koye Pharmaceuticals,” David Liu, CEO of Sonde Health said on 24 Aug 2022.
“Partnering directly with pharmaceutical companies allows us to take a more targeted and engaging approach with prospective patients, aligning their needs with the most impactful therapeutics.
“While there’s no cure for COPD, this new vocal biomarker will allow physicians to better manage their patients’ symptoms using early monitoring and constant engagement to ensure those impacted by COPD get on the right treatment plans early and often,” said Liu.
“We have been keen on utilizing an accessible platform with digital biomarkers that will both aid physicians in identifying and understanding their patients’ conditions better and also make it easier for patients with chronic respiratory conditions to monitor their health in the least invasive way possible,” said Preetish Toraskar, Founder and Director at Koye Pharmaceuticals.
“This partnership with Sonde Health is exactly what we were looking for.
“Not only is Sonde at the forefront of vocal biomarker technology, but their extensive experience in respiratory health will prove invaluable as we work to get this debilitating condition under control in India,” he said.
Sonde Health has previously developed and commercialized vocal biomarker technology to detect and monitor respiratory impairment. In early 2022, the company partnered with GN Group, a leading global manufacturer of hearing instruments and audiological diagnostics equipment and headsets, to create vocal biomarker technology to detect Mild Cognitive Impairment.
Koye Pharmaceuticals Pvt Ltd, founded in 2013, has expanded its operations to run across the length and breadth of the country aided by their strong distribution network. fiinews.com
